Across TCGA pan-cancer cohorts, IGHV1-2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGHV1-2 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGHV1-2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHV1-2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where IGHV1-2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.184	1.000	.006	28	view →
CCRCC	OS	Median	All	1.000	0.914	.027	9	view →
PDAC	DFS	Quartile	II,III,IV	0.500	0.291	.020	4	view →
HNSC	DFS	Tertile	III,IV	1.000	0.623	.040	3	view →
GBM	OS	Quartile	All	0.702	0.926	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IGHV1-2 tumor-vs-normal RNA expression · all IGHV1-2 data types